Physician profile
Cassidy Alexandre
NPI 1922494715
$6,271.82
in general payments reported to CMS, 2019-2025
27 companies · $1,978 in 2025
The $1,978 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $358 · 2022: $795 · 2023: $1,376 · 2024: $1,764 · 2025: $1,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,730 · Education: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,730.23 |
| Education | $388.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $889.90 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $796.60 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $763.80 | 2021-2025 | Rinvoq, Skyrizi, Linzess |
| Boston Scientific Corporation | $708.45 | 2021-2024 | Spyglass, Exalt Model D, Hydratome Rx 44 |
| Takeda Pharmaceuticals U.S.A., INC. | $624.01 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $478.91 | 2022-2025 | Livdelzi |
| Ardelyx, INC. | $403.41 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $185.98 | 2024-2025 | Sucraid, Sucraid |
| Celgene Corporation | $184.09 | 2022-2024 | Zeposia |
| Amgen INC. | $151.11 | 2025 | Uplizna |
| Intercept Pharmaceuticals, INC. | $150.94 | 2022-2025 | Ocaliva |
| Pfizer INC. | $133.67 | 2024-2025 | |
| Lilly USA, LLC | $115.40 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $98.76 | 2022-2024 | Linzess |
| Madrigal Pharmaceuticals | $91.39 | 2024-2025 | Resmetirom, Rezdiffra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $87.96 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $65.45 | 2023 | Dupixent |
| Ferring Pharmaceuticals INC. | $56.81 | 2023-2024 | Rebyota |
| Fresenius Kabi USA, LLC | $52.81 | 2023-2024 | Idacio |
| Nestle Healthcare Nutrition INC. | $50.27 | 2023 | |
| Phathom Pharmaceuticals, INC. | $35.08 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $34.88 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $29.78 | 2024 | Bylvay |
| Merck Sharp & Dohme LLC | $24.01 | 2024 | Keytruda |
| Exact Sciences Corporation | $22.83 | 2025 | The Cologuard Plus Collection Kit |
| Celltrion USA INC. | $21.81 | 2025 | Vegzelma |
| Evoke Pharma, INC. | $13.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassidy Alexandre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.